The day in pharma, read in minutes.
NewsFDA Updates Accelerated Approval Clinical Benefit List
FDA's updated verified clinical benefit list covers 14 non-malignant and neurological AA conversions, offering regulatory teams concrete timeline benchmarks.
AbbVie Invests $217M to Modernize Barceloneta Biologics Campus

Valneva Sweden Builds Cross-Functional GMP Culture

Ichnos Glenmark Submits IND for Trispecific ISB 2301

IGI Files IND for Multi-Mechanism Solid Tumor Immunotherapy

Latest news
11 storiesBiocon Secures EU Approval for Pertuzumab Biosimilar
Biocon secures EMA marketing authorisation for a pertuzumab biosimilar covering HER2-positive breast cancer across multiple disease stages in the EU.

Pfizer Signs $2.63B Starna CAR-T Deal for Autoimmune Disease
Pfizer's $2.63B CAR-T licensing deal with Starna Therapeutics raises immediate questions for cell therapy CDMOs on GMP readiness and manufacturing capacity.

Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader
Evotec and BMS secure a second FDA IND acceptance for a CELMoD degrader, with Phase 1 entry targeted for 2027.

Genzyme Wins FDA Approval for Infilbray in Type 3 Gaucher
FDA approves Infilbray (venglustat) for GD3 neurological symptoms, raising CNS-penetrant GMP and process validation considerations for Genzyme.

EktaH Advances NKS-3 Obesity Drug into Phase IIa
EktaH enrolls first patient in Phase IIa obesity trial in Tunisia, backed by €2.4M in new funding for NKS-3.

Innate Pharma Reports Phase 1 Results for IPH4502 ADC
Innate Pharma's IPH4502 Phase 1 data show linker stability signal and 33% ORR at MTD; dose optimization begins H1 2027.

Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib
Merck halts Phase 3 BELLWAVE-011 for nemtabrutinib after an external DMC finds risk-benefit balance unfavorable, closing a late-stage BTK inhibitor program.

FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA
FDA's GRDP expands to all NMEs and BLAs in January 2027, requiring a 10-day post-approval request window and confirmed foreign-market submissions.

FDA Draft Guidance Sets Bayesian Methods for Drug Trials
FDA draft guidance FDA-2025-D-3217 defines acceptable Bayesian methodology use for primary inference in NDA, BLA, and IND clinical trial submissions.

Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC
FDA grants neladalkib accelerated approval for ALK-positive NSCLC, triggering confirmatory trial and manufacturing scale-up obligations for Nuvalent.

Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC
FDA approves Lembaz for infantile-onset NPC using external control survival data, setting a precedent for rare disease regulatory strategy.

Worth your time this week

Viatris Completes $1.65B Acquisition of Pacira BioSciences

Greenwich LifeSciences Gets Two Abstracts Accepted for SABCS 2026

Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board
